MannKind | MNKD - Loan Capital


MannKind reported $545.13M in Loan Capital for its fiscal quarter ending in June of 2026.





Loan Capital Change Date
Adma Biologics USD 192.84M 745K Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
Eli Lilly USD 47.86B 8.49B Jun/2026
Halozyme Therapeutics USD 1.94B 1.79M Jun/2026
Insmed USD 543.51M 1.3M Jun/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
MannKind USD 545.13M 2.93M Jun/2026
Merck USD 51.08B 4.41B Jun/2026
Minerva Neurosciences USD 0 86.58M Sep/2024
Novavax USD 246.3M 200K Dec/2025
Novo Nordisk DKK 18.61B 100.56B Jun/2026
Pfizer USD 60.5B 70M Jun/2026
Sanofi EUR 14.65B 806M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026